



## **Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference**

June 26, 2025

WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT.

A live and archived webcast of the presentation will be accessible on the Events page of <https://www.aclaristx.com/>. The webcast will be available on the Aclaris website for at least 30 days.

### **About Aclaris Therapeutics, Inc.**

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com) and follow Aclaris on [X](#) (formerly Twitter) at @AclarisTx and on [LinkedIn](#).

### **Aclaris Therapeutics Contact:**

#### **Will Roberts**

Senior Vice President

Corporate Communications and Investor Relations

(484) 329-2125

[wroberts@aclariastx.com](mailto:wroberts@aclariastx.com)



Source: Aclaris Therapeutics, Inc.